Retiro De Equipo (Recall) de Device Recall MEDRAD Avanta Fluid Management Injection System

Según U.S. Food and Drug Administration, este evento ( retiro de equipo (recall) ) involucró a un dispositivo médico en United States que fue producido por Medrad Inc.

¿Qué es esto?

Una corrección al equipo o acción de retiro tomada por el fabricante para abordar un problema con un dispositivo médico. Los retiros (recalls) ocurren cuando un dispositivo médico está defectuoso, cuando puede poner en riesgo la salud, o cuando simultáneamente está defectuoso y puede poner en riesgo la salud.

Más información acerca de la data acá
  • Tipo de evento
    Recall
  • ID del evento
    59167
  • Clase de Riesgo del Evento
    Class 2
  • Número del evento
    Z-2866-2011
  • Fecha de inicio del evento
    2011-06-02
  • Fecha de publicación del evento
    2011-07-22
  • Estado del evento
    Terminated
  • País del evento
  • Fecha de finalización del evento
    2012-06-05
  • Fuente del evento
    USFDA
  • URL de la fuente del evento
  • Notas / Alertas
    U.S. data is current through June 2018. All of the data comes from the U.S. Food and Drug Administration, except for the category Manufacturer Parent Company.
    The Parent Company was added by ICIJ.
    The parent company information is based on 2017 public records.
  • Notas adicionales en la data
    Injector and syringe, angiographic - Product Code DXT
  • Causa
    Event was initially intended to be a product enhancement of the medrad avanta fluid management injection system. upgrades were initiated in october, 2007. observance of a possible increase in complaints and adverse event reporting resulted in the firm issuing "important product use reminder" to remind users of proper procedures for using the system and the need for diligence in reducing air embo.
  • Acción
    Medrad Inc., sent two types of "MEDICAL DEVICE FIELD CORRECTION" notifications on June 2, 2011 to all affected customers. 1. To those customers who Avanta Systems have already undergone market withdrawal and thus have been upgraded, the notification provided customer awareness that prior action should be considered a field correction. The letter stated that NO action is required since their system(s) has already been upgraded. If you have any questions, concerning these activities contact the Director of Quality Systems at (724) 940-6905. 2. To those customers whose Avanta Systems have not yet been upgraded through market withdrawal, the notification informed customers that the recalling firm is undertaking a Field Correction to upgrade their system(s). The letter included a step by step guide that will allow customers to verify that their system(s) has NOT been upgraded. Customers are instructed to complete and fax this form to MEDRAD at (412) 406-0941. If you have any questions, concerning these activities contact the Product Manager at (412) 767-2400, extension 8401.

Device

  • Modelo / Serial
    Catalog numbers: AVA 500 TABL, AVA 500 PEDL
  • Clasificación del producto
  • Clase de dispositivo
    2
  • ¿Implante?
    No
  • Distribución
    Worldwide Distribution -- (USA) (nationwide) including the state of Puerto Ricoand the countries of: AE, AL, AT, BE, BG, BR, CA, CH, CO, CY, DE, DK, DO, ES, FI, FR, GB, HK, HR, HU, IE, IL, IS, IT, JO, JP, KR, KW, LY, MA, MT, MX, MY, NL, PA, PH, PK, PT, QA, RS, RU, SA, SE, SG, SI, TR, VI, and ZA.
  • Descripción del producto
    MEDRAD Avanta Fluid Management Injection System, Catalog numbers: AVA 500 TABL, AVA 500 PEDL || Product Usage: Administration of intravascular radio-opaque contrast media and common flushing solutions during angiographic procedures.
  • Manufacturer

Manufacturer

  • Dirección del fabricante
    Medrad Inc, 1 Medrad Dr, Indianola PA 15051-9759
  • Source
    USFDA